In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Edwards: Will a Biotech Deal Strategy Work For a Device Company?

Executive Summary

More than two years after being spun-out as Baxter's cardiovascular group, Edwards Lifesciences is establishing its identity as an independent company. A large part of this initial process has focused on which product lines to retain, which to divest, and what new areas to get into. Edwards emerged in the unusual position of having market leadership positions in several product areas, most significantly heart valves. But slow growth in those markets is limiting the extent to which they can drive overall company growth. Edwards' new strategy is to focus on advanced--stage cardiovascular disease with its primary customers being cardiac surgeons. Resource-constrained following the spin-out, the company is relying on a strategy unusual for device companies--alliance, rather than acquisitions--to expand its product offerings. But as the treatment of cardiovascular disease continues to rely increasingly on interventional techniques, the challenge for Edwards is to build a sustainable, broad-based business around selling to cardiac surgeons.

You may also be interested in...

Building Device Companies Large & Small: An Interview with Dave Chonette

Dave Chonette is among the device industry's pioneers, having helped build both large companies--notably, Edwards Lifesciences--and the venture-based innovation model for creating start-ups to provide a continuing source of new products. This interview is adapted from a presentation at the 2007 Phoenix Medical Device CEOs conference, at which Chonette received the group's Lifetime Achievement award.

Edwards Lifesciences: Staking New Ground in Cardiovascular Devices

Over the past seven years, since its spin off from Baxter International, Edwards Lifesciences has built a cardiovascular business to challenge the industry giants. In this interview, CEO Mike Mussallem looks back over a 20-year career whose highlights include surviving the Baxter/American Hospital Supply merger and formulating Edwards' vision.

OrbusNeich: Tissue Engineering Meets Coronary Stents

While most companies are developing new ways to deliver drugs off of stents, OrbusNeich is looking to capture circulating endothelial progenitor cells onto its device to promote healing naturally, without drugs.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts